High cost, three doses make ZyCoV-D last choice among Covid vaccines

Hospitals say stocks of Covishield, Covaxin have piled up, cite lack of needle-free vaccine applicators      

published on : 14th October 2021

'Lack of vaccine applicators delaying ZyCoV-D launch', say government officials

The Ahmedabad-based company had projected the vaccine as a painless vaccine that has to be administered in three doses.

published on : 12th October 2021

ZyCoV-D to be introduced in Covid vaccination drive shortly: Government

As far as the price at which it will be procured is concerned, Union Health Secretary Rajesh Bhushan told a press conference that the government is in talks with the manufacturer.

published on : 30th September 2021

Zydus Cadila vaccine likely to seek 2-dose approval, not 3

The permission granted by DCGI in August was for a three-dose schedule, which was tested for efficacy in the Phase 3 clinical trials.

published on : 4th September 2021

Zydus Cadila's COVID-19 vaccine to be available from first week of October

Further, a decision on whether all children or only those with co-morbidities will be administered the COVID-19 vaccine on priority has not yet been taken, the government said on Thursday.

published on : 27th August 2021

Hope to start supply of ZyCoV-D vaccine by mid to end September: Zydus Group MD

Sharvil Patel said Zydus Cadila is actively looking at ramping up manufacturing both domestically through partnerships and also outside of the country.

published on : 21st August 2021

'A momentous feat': PM Modi after Zydus Cadila's COVID vaccine gets emergency use authorisation

ZyCoV-D has received approval for emergency use authorisation from the Drug Controller General of India and it will be administered to people 12 years and above.

published on : 20th August 2021

Zydus Cadila's Covid vaccine gets approval, to be administered to children in India

This is the world's first DNA-based vaccine against the coronavirus, and this three-dose vaccine when injected produces the spike protein of the SARS-CoV-2 virus and elicits an immune response.

published on : 20th August 2021

Zydus Cadila likely to get emergency use approval for its COVID vaccine this week: Sources

Zydus Cadila last month had said that it has applied for emergency use authorisation (EUA) with the Indian Drug regulator for its three-dose COVID-19 vaccine ZyCoV-D.

published on : 9th August 2021

Zydus seeks nod for its Covid vaccine ZyCoV-D, claims 66.6% efficacy against symptomatic infection

In its submission, the company claimed that in the interim analysis, based on 90 confirmed Covid-19 cases, no moderate, severe disease or deaths were reported in those vaccinated with ZyCoV-D. 

published on : 1st July 2021

The need to prioritise vaccination for children

There are children among the 23 crore Indians who have been pushed into poverty and will never return to class. Prolonged school closures have reversed decades of gains in education

published on : 30th June 2021

India's first Covid vaccine for kids gets closer to reality, may get DGCI nod soon

ZyCoV-D, has been sent by pharmaceutical firm Zydus Cadila for emergency use authorisation to the DGCI after its clinical trials ended successfully in the country.

published on : 20th June 2021

20 children successfully undergo trials of indigenous ZyCoV-D vaccine at Karnataka hospital

None of the children who underwent the clinical trials are having any side effects or other health complications two months after the vaccines were administered to them, said Dr Amit Bhate

published on : 20th May 2021

India could get fourth Covid vaccine as Zydus Cadila set to seek nod for ZyCoV-D

If the regulatory approvals come through, the vaccine, being called ZyCoV-D now, will be the first DNA vaccine, licensed for use in humans.

published on : 18th May 2021